As specific TTR variants that destabilize TTR structures were known to be associated with either amyloid cardiomyopathy or familial amyloid neuropathy, the tafamidis story also highlights the power of human genetics to elucidate viable therapeutic strategies. This evidence concerns the gene TTR and cardiac amyloidosis.